@TapKadia

Tapan Kadia, MD - Leukemia Doc at MD Anderson Cancer Center Leukemia, clinical/translational research. Views, posts and opinions shared are my own.

 Houston, TX
Joined July 2012
  • Tweets4.7K
  • Following219
  • Followers3.8K
298Media
Replying to @TaylorJ_MD @drsangeetmd @SylvesterCancer @ASH_hematology @ASHClinicalNews
Nice photo & well done #ASH26 @ASH_hematology 😀!!!! @TapKadia @JenMarvinPeek @HannahGoulart
1
6
399
Tapan Kadia retweeted
VJHemOnc
@VJHemOncSep 20
🧬 Session 8 at #iwAL26: Transplantation in AML, chaired by Charles Craddock (@charliecraddock) & Victoria Potter! Charles Craddock on reducing relapse risk post-transplant, Samer Srour on precision-engineered T-cell therapy for alloHSCT, then a debate on pre-transplant intervention in MRD+ AML CR1 🥊 @TapKadia (yes) vs. Victoria Potter (no) 🥊 #iwAL #AML #LeuSM
1
5
13
851
Tapan Kadia retweeted
OncLive.com
@OncLiveSep 20
Ready for The Five Under 5 🕘? Here is your go-to roundup of the top 5 #OncLiveTV 📹 videos of last week. @JuliaRotow @TapKadia @drgandara @GabyHobbs @DanaFarber @UCD_Cancer @MassGeneralNews #hematology #oncology Watch the clips that made the list 🔗: onclive.com/view/five-under-…
1
4
8
1,632
🏆First #Leukemia fellowship #Alumni of @UTMDAnderson gathering after #SOHO26 🔥 Such a great time connecting with friends, colleagues, & former fellows ⏭️ Join us for future editions coming up at the upcoming meetings – at West University Place, TX
1
7
1
54
3,270
Tapan Kadia retweeted
Lisa Palacios@Lisa_PalaciosSep 12
Saturday, Sept 12 — Session XIV: Next Questions Join @TapKadia at #SOHO2026 for Next Questions: Acute Myeloid Leukemia, a forward‑looking discussion on the key challenges, opportunities, and unanswered questions shaping the future of #AML research and patient care. @UTMDAnderson
1
5
4
496
Tapan Kadia retweeted
UT MD Anderson
@UTMDAndersonSep 10
A second opinion at UT MD Anderson revealed Jessica Smither actually had two different types of leukemia, instead of only one. How our Dr. Tapan Kadia's expertise changed her treatment plan and put both cancers into remission. @TapKadia #EndCancer
Houston Chronicle
@HoustonChronSep 10
Blurred vision, an 80-pound weight loss and rapidly worsening symptoms left a Houston woman fighting for her life — until MD Anderson doctors took another look. houstonchronicle.com/health/…

She went to a doctor for blurred vision. She found out she had weeks to live.

Blurred vision, an 80-pound weight loss and rapidly worsening symptoms left a Houston woman fighting for her life — until MD Anderson doctors took another look.

houstonchronicle.com
10
31
7,522
Tapan Kadia retweeted
Tapan Kadia@TapKadiaMay 12
Our most recent update of CLAD+LDAC+Ven now published - almost 200 pts with ~3yr f/u ; CR rate 84% and 92% in TP53 wildtype. @alexbataller onlinelibrary.wiley.com/doi/…
1
10
27
2,216
👏Important new paper from our group led by .@TapKadia & @AlexBataller 👉just out in @AjHematology | #Cladribine #leusm #endcancer | @sanamloghavi onlinelibrary.wiley.com/doi/…
16
58
3,743
Tapan Kadia retweeted
UT MD Anderson
@UTMDAndersonMay 12
Results from a Phase 2 trial showed that a lower-intensity treatment regimen may be highly effective in some subsets of patients with acute myeloid leukemia. Learn more: spr.ly/6014BBQgAk @tapkadia #EndCancer

Low-intensity combination therapy yields strong outcomes in hard-to-treat AML

This novel lower-intensity regimen yielded high rates of remission in older or medically fragile patients with acute myeloid leukemia (AML), according to researchers at The University of Texas MD...

mdanderson.org
5
1
10
1,418
Our most recent update of CLAD+LDAC+Ven now published - almost 200 pts with ~3yr f/u ; CR rate 84% and 92% in TP53 wildtype. @alexbataller onlinelibrary.wiley.com/doi/…
1
10
27
2,216
Triple- nucleosides plus venetoclax result in outstanding outcomes in older #AML doi.org/10.1002/ajh.70328 @AjHematology @UTMDAnderson
4
32
3
129
9,738
Just wrapped up an incredible ASH convention! Grateful for the opportunity to be part of the leukemia fellowship @MDAndersonNews @garciamanero @TapKadia @r_sazevedo #leukemia #ASH25 @Apsingh_MD
1
2
27
2,315
Great presentation by @jenweiying summarizing the frontline data with Oral Dac Ven Revumenib in patients with newly diagnosed NPM1-m and KMT2a-r AML. #ASH2025 @MDAndersonNews
1
7
3
33
9,442
Tapan Kadia retweeted
PeerView
@PeerView5 Dec 2025
Big thanks to Drs. David A. Sallman, @Tapkadia and @dremmasearle for an outstanding #ASH25 #AML session—packed with practical insights for everyday clinical care. 📺 Catch the replay: bit.ly/2025-AML-T Grateful for grant support from @JNJInnovMed, @kuraoncology and @Syndax, and for our collaboration with @HealthTree! #CME #MedEd
5
10
506
#ASH25 | Wow!! Thanks 🙏 to @ASH_hematology for featuring our @MDAndersonNews Leukemia team in the #ASH25 Program Guide with the reminder save the date for #ASH26 !!!!! | @TapKadia @drsangeetmd @JenMarvinPeek @HannahGoulart @doctorpemm @CRausch_PharmD @FadiHaddad_MD @NitinJainMD
4
11
50
2,310
Our latest from @MDAndersonNews sharing the largest series of these cases to date. onlinelibrary.wiley.com/doi/… @jenweiying @TapKadia @BrJHaem

MECOM fusion partner and bone marrow blast percentage influence outcomes of patients with MECOM...

MECOM rearrangements (MECOM-r) are acute myeloid leukaemia (AML)-defining, regardless of blast percentage or MECOM fusion partner. We sought to investigate if blast percentage or MECOM-r partner was...

onlinelibrary.wiley.com
6
19
1,648
Read the cell, guess the genetics. #HemePath #Genetics #leusm #AMLsm 🔬🧬🩸
5
108
5
294
19,493
We report incidence of NPM1-wildtype relapses in pts treated with VEN-based frontline tx in AML.   🔴Overall, absolute # of relapses in NPM1 AML after VEN is ⬇️  🔴the fraction of NPM1-wildtype relapses ⬆️ with the⬆️ intensity of chemo backbone added to VEN.  🔴 NPM1 wildtype relapses occur later and often had MR mutations.  And ALL (8/8) had a different flow immunophenotype compared to original AML.  🔴We proposed that these were ‘new’ AMLs, that arose from common preleukemic (CH) precursor, but that the original NPM1-mutated AML was ‘cured’. onlinelibrary.wiley.com/acti… @AjHematology
Sanam Loghavi, MD صنم لغوی 🔬🧬
@sanamloghavi28 Aug 2025
American Journal of Hematology | Blood Research Journal | Wiley Online Library #hemepath onlinelibrary.wiley.com/doi/…

Outcomes and Patterns of Relapse of NPM1 Mutated Acute Myeloid Leukemia Treated With Venetoclax...

Click on the article title to read more.

onlinelibrary.wiley.com
7
15
2
83
8,251
Investigational CPX-531 plus venetoclax may be a salvage therapy option for relapsed or refractory #AML @TapKadia @AjHematology sohoinsider.com/leukemia/acu…

Investigational CPX-531 plus venetoclax may be a salvage therapy option for relapsed or refractory...

By Kerri Fitzgerald A study assessed CPX-531 plus venetoclax in patients with relapsed or refractory acute myeloid leukemia (AML) and found that the combination was particularly effective in first...

sohoinsider.com
3
12
937
Triplet therapy maintains, improves quality of life in relapsed/refractory myeloma sohoinsider.com/news/belanta…

Triplet therapy maintains, improves quality of life in relapsed/refractory myeloma

By: Kerri Fitzgerald The combination of belantamab mafodotin, bortezomib, and dexamethasone generally maintained or improved health-related quality of life (HRQOL) in patients with relapsed or...

sohoinsider.com
3
10
841
Load more